阿帕他胺联合雄激素剥夺治疗用于转移性去势敏感性前列腺癌临床亚组患者:随机临床TITAN研究的亚组分析
基于III期随机TITAN研究的事后分析,评估阿帕他胺(240 mg/日)联合ADT对比安慰剂联合ADT在mCSPC不同疾病负荷、转移数目及转移时机亚组中的疗效。结果显示,无论疾病负荷和转移时机如何,阿帕他胺联合ADT均带来稳健获益且安全性无差异,支持在mCSPC中早期强化阿帕他胺治疗。
要点
- 阿帕他胺联合ADT在同步/高负荷、同步/低负荷、异时/高负荷及异时/低负荷亚组中均改善OS。
- 其他临床结局在所有亚组中均获改善,且安全性特征相似。
- 寡转移性疾病患者观察到最有利的结局。
核心结论
- TITAN患者无论疾病负荷和转移呈现时机如何,阿帕他胺联合ADT均带来稳健获益且安全性无差异,支持在mCSPC中早期强化阿帕他胺治疗。
研究设计与样本
- III期随机TITAN研究(NCT02489318)的方案定义及事后亚组分析,纳入接受阿帕他胺240 mg/日(n=525)或安慰剂(n=527)联合ADT的mCSPC患者。
- 亚组按疾病负荷(高负荷:内脏转移和≥1处骨转移,或≥4处骨病灶且至少1处位于脊柱/骨盆之外)、转移呈现时机(同步:初诊时;异时:局限性疾病后)及寡转移(≤5处纯骨转移)或多转移(>5处骨转移±其他部位,或≤5处骨转移加其他部位)定义。
- 采用Cox比例风险模型评估总生存期(OS)、影像学或第二次进展生存期、至前列腺特异性抗原进展或去势抵抗时间。
主要发现
- 1052例患者中,高负荷、同步、同步/高负荷、同步/低负荷、异时/高负荷和异时/低负荷疾病分别占63%、81%、54%、27%、5.7%和8.0%。
- 同步/高负荷亚组OS获益 favoring 阿帕他胺联合ADT对比单纯ADT:HR=0.68(95%CI:0.53-0.87;p=0.002)。
- 同步/低负荷亚组OS:HR=0.65(95%CI:0.40-1.05;p=0.08);异时/高负荷亚组OS:HR=0.69(95%CI:0.33-1.44;p=0.32)。
- 异时/低负荷亚组OS:HR=0.22(95%CI:0.09-0.55;p=0.001)。
- 无论亚组如何,阿帕他胺均改善其他临床结局,且安全性特征相似;寡转移性疾病患者观察到最有利的结局。
临床怎么用
- TITAN患者无论疾病负荷和转移呈现时机如何,阿帕他胺联合ADT均带来稳健获益且安全性无差异,支持在mCSPC中早期强化阿帕他胺治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whether disease burden in patients with metastatic castration-sensitive prostate cancer (mCSPC) predicts treatment outcomes is unknown. We assessed apalutamide treatment effect in TITAN patients with mCSPC by disease volume, metastasis number and timing of metastasis presentation. METHODS: These protocol-defined and post hoc analyses of the phase III randomised TITAN study evaluated clinical outcomes in patients receiving 240 mg/day apalutamide (n = 525) or placebo (n = 527) plus androgen-deprivation therapy (ADT). Subgroups were defined by volume (high: visceral and ≥1 bone metastases or ≥4 bone lesions with ≥1 beyond vertebral column/pelvis), development of metastases per conventional imaging (synchronous: at initial diagnosis; metachronous: after localised disease) and oligometastases (≤5 bone-only metastases) or polymetastases (>5 in bone ± other locations or ≤5 in bone plus other locations). Overall survival (OS), radiographic or second progression-free survival, and time to prostate-specific antigen progression or castration resistance were assessed using Cox proportional hazards models. RESULTS: Of 1052 patients, 63%, 81%, 54%, 27%, 5.7%, and 8.0% had high-volume, synchronous, synchronous/high-volume, synchronous/low-volume, metachronous/high-volume, and metachronous/low-volume disease, respectively. The OS benefit favoured apalutamide plus ADT versus ADT alone in synchronous/high-volume (hazard ratio = 0.68 [95% confidence interval: 0.53-0.87]; p = 0.002), synchronous/low-volume (0.65 [0.40-1.05]; p = 0.08), metachronous/high-volume (0.69 [0.33-1.44]; p = 0.32) and metachronous/low-volume (0.22 [0.09-0.55]; p = 0.001) subgroups. Apalutamide improved other clinical outcomes regardless of subgroup, with similar safety profiles. Most favourable outcomes were observed in oligometastatic disease. CONCLUSION: TITAN patients derived a robust benefit with apalutamide plus ADT regardless of disease volume and timing of metastasis presentation without differences in safety, supporting early apalutamide intensification in mCSPC. CLINICAL TRIAL REGISTRATION: NCT02489318.
引用
- Merseburger AS, Agarwal N, Bhaumik A, et al. Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study. Eur J Cancer. 2023. PMID: 37708629. doi:10.1016/j.ejca.2023.113290
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。